# NCT05358639 (NCT05358639)

> Combination of Olaparib and Navitoclax in Women with HGSC and TNBC

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT05358639
- Phase: PHASE1
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Sunnybrook Health Sciences Centre
- Conditions: High Grade Serous Carcinoma; Triple Negative Breast Cancer; Ovarian Cancer
- Interventions: Olaparib tablet; Navitoclax
- Enrollment: 36
- Primary outcome: To define a dose and schedule of navitoclax (Recommended Phase II Dose, RP2D) that can be combined safely with Olaparib in women with metastatic recurrent high grade serous ovarian cancer (HGSC) and triple negative breast cancer (TNBC) for further study

## Preliminary discovery

Commentary in our index that names this trial so far. Final coverage is set when the report is built.

- Bluesky threads: 67
- Podcasts: 2

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=nct05358639

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT05358639", "email": "<work email>"}; the inbox owner confirms by the emailed link.